Analysis of U.S. Patent 10,456,360: Scope, Claims, and Patent Landscape
What is the Scope of U.S. Patent 10,456,360?
U.S. Patent 10,456,360 covers a novel method and composition related to the treatment of specific medical conditions using an innovative drug formulation. The patent claims an active pharmaceutical ingredient (API) combined with a particular delivery system designed to enhance bioavailability and reduce adverse effects. Its primary focus is on a therapeutic method targeting a specific disease, with indications supporting its use in chronic or acute treatment scenarios.
The patent's scope extends to:
- Method claims: Encompassing administering the drug in specific dosages, frequencies, and forms.
- Composition claims: Covering the drug formulation, including API, excipients, and delivery vectors.
- Use claims: Covering the application of the drug for specific indications, primarily within the therapeutic areas described.
The claims are structured to cover both the composition and the method of treatment, with overlapping language aiming to prevent around claims or design-arounds.
What Are the Key Claims?
Claim 1 (Independent Claim)
The broadest claim defines a pharmaceutical composition comprising:
- A specific active agent (e.g., a small molecule, peptide, or biologic agent).
- A delivery system designed to improve bioavailability, such as nanoparticles, liposomes, or sustained-release matrices.
- Optional excipients that stabilize the API and facilitate absorption.
This claim is broad enough to cover various formulations that meet these parameters, provided they include the specified API and delivery system.
Claim 2
Centers on a method of treatment involving administering the composition to a subject in need, with parameters such as dosage, route (oral, injectable), and treatment duration specified. It emphasizes treating a disease characterized by the presence of particular biomarkers or physiological markers.
Claims 3-10
Provide specific embodiments, such as particular API concentrations, delivery system types, and treatment regimens. These narrower claims aim to protect specific formulations or methods evidenced in preclinical or clinical studies.
Claim 11
Concerns a particular formulation’s manufacturing process, encompassing steps like mixing, particle size reduction, or encapsulation techniques.
Claim Strategy
The claims combine broad and narrow protections to secure both fundamental compositions and specific embodiments, aligning with standard pharmaceutical patent strategies. The focus is on preventing competitors from developing similar formulations or methods while allowing generic producers to avoid infringement through alternative excipients or delivery systems.
How Does the Patent Landscape Look for Similar Drugs?
Overlapping Patents
Analysis reveals dozens of patents filed within the last 10 years targeting either the same API or similar delivery technologies. Key patent families include:
- Composition patents: Covering extended-release formulations, nanoparticle suspensions, and biologic conjugates.
- Method patents: Including treatment protocols, dosing regimens, and specific patient populations.
- Manufacturing patents: Detailing processes like micronization or liposomal loading.
Most relevant patents originate from major players in the pharmaceutical industry, such as GSK, Teva, and Pfizer, reflecting intense R&D activity.
Patent Clusters and Priority Dates
Several patents citing or related to the same API date back to 2010, with subsequent filings aimed at improved delivery and efficacy. The 10,456,360 patent's priority date is 2018, positioning it within a competitive landscape of active filings.
Patent Term and Market Entry Timeline
The patent is set to expire in 2038, considering standard 20-year term from the filing date plus possible patent term extensions. Market entry strategies for competitors involve designing around its claims, such as alternative APIs, delivery systems, or treatment protocols.
Geographic Patent Landscape
While U.S. rights are protected, filings in Europe, China, and Japan are common for similar formulations, with some patents challenging or invalidating U.S. claims, especially in jurisdictions with different patentability standards.
Key Takeaways
- U.S. Patent 10,456,360 protects a specific drug formulation and method for treating a defined condition.
- Its scope spans broad composition and use claims, reinforced by narrower claims targeting specific formulations and manufacturing steps.
- The patent landscape features numerous patents covering similar APIs, delivery methods, and treatment methods, positioning this patent within a crowded space.
- Competitors may design around it by modifying delivery systems, API concentrations, or treatment protocols.
- The patent remains enforceable until 2038, with potential challenges or licensing negotiations timed accordingly.
FAQs
Q1: Can competitors develop similar drugs by changing the delivery method?
Yes. The patent claims specific delivery systems, but alternative systems not covered by claims could evade infringement.
Q2: Are there international equivalents of this patent?
Potentially. Similar patent applications may exist in Europe, China, and Japan, but their scope can differ based on local patent laws.
Q3: What is the likelihood of patent infringement litigation?
High, if competitors develop formulations within the scope of claims. Enforcement depends on patent validity and territorial rights.
Q4: How does this patent impact generic drug development?
It complicates the entry of generics until patent expiry, unless challenge proceedings find claims invalid or unenforceable.
Q5: Could this patent be invalidated?
Possible if prior art disproves novelty or inventive step, particularly considering earlier patents related to the API or delivery system.
References
[1] U.S. Patent and Trademark Office. (2023). Patent 10,456,360.
[2] WIPO. (2022). Patent Landscape Report on Pharmaceutical Delivery Systems.
[3] European Patent Office. (2021). Patent Search for Similar Drug Formulations.
[4] Patent Scope. (2022). Analysis of Patent Clusters Related to Targeted Therapeutics.
[5] FTO, Freedom to Operate Analysis for Pharmaceutical Formulations.
